# SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

> **NCT00460798** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 356 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **OTHER:** Sutent: observational study

## Key facts

- **NCT ID:** NCT00460798
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2010-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460798, "SUTENT® In The First Line Treatment Of Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00460798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*